SEO URLwww.firestrike.ai/deals/avidity-biosciences-novartis-acquisition-2026
acquisitionAnnounced · Mar 2, 2026BiopharmaceuticalSource · CredibleArticle · Factual
Novartis acquires Avidity Biosciences
David Najork · Founding Software Engineer
Published · Updated · 1 min read
Deal value
$12B
Target
Avidity Biosciences
NASDAQ: RNA · San Diego, California
Acquirer
Novartis
Full Acquisition
Status
Pending
Novartis agreed to acquire Avidity Biosciences. Reported deal value: $12B. Status: Pending. Sector: Biopharmaceutical. Target headquarters context: San Diego, California, United States.
This page summarizes publicly available information about the transaction as of 2026-03-02. Figures and status may change as filings and press coverage update.
Novartis AG today announced that it has successfully completed its acquisition of Avidity Biosciences , Inc.
Deal timeline
Announced
Mar 2, 2026 · biospace.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Biopharmaceutical with a reported deal value of $12B. Figures and status may change as sources update.
Sources: biospace.com · Primary article · FireStrike proprietary index